Sermorelin is a lab-made copy of the front end of GHRH — growth-hormone-releasing hormone, the brain's signal that tells the pituitary to release growth hormone. Of the GHRH-analog family, it's the plain baseline: short, unmodified, and — unlike its research-peptide cousins — a molecule with a real approved-drug history.
In plain terms: it's the original, no-frills "release your own growth hormone" peptide, and it used to be a prescription medicine.
What it is
Natural GHRH is 44 amino acids long, but scientists discovered that just the first 29 — GHRH(1-29) — keep the full growth-hormone-releasing power1. Sermorelin is exactly that 29-amino-acid fragment. That's why it's called the shortest peptide with complete GHRH activity, and it's the same base sequence that CJC-1295 is engineered from. Sermorelin is the un-modified version; CJC-1295 adds the tweaks (and, in the DAC form, an albumin anchor) that make it last for days.
Like every GHRH analog, sermorelin pulls the GHRH lever — it prompts the body's own growth hormone rather than supplying growth hormone directly. The opposite lever, the ghrelin/GHS receptor, is what ipamorelin uses.
The part most pages skip: it was an approved drug
Here's the history that gives sermorelin unusual credibility for a "peptide." It was FDA-approved as Geref and used in real clinical medicine two ways1:
- As a diagnostic test — a sermorelin injection reliably provokes a growth-hormone pulse, so doctors used it to test whether a child's pituitary could respond (a "GHRH stimulation test").
- As a treatment — for children with growth-hormone deficiency, to stimulate their own growth-hormone output.
Geref was later withdrawn from the market for commercial reasons — not because of a safety scandal — and sermorelin now exists mostly as a compounded peptide rather than a branded drug.
What the studies actually found
| Study | Model | Key result | Year |
|---|---|---|---|
| Prakash & Goa (review)1 | Human (pediatric use) | Documented GHRH(1-29) as the shortest fully-active fragment; reliable as a GH-stimulation test and a treatment for childhood GH deficiency | 1999 |
| Geref (FDA approval)1 | US regulatory | Marketed as an approved drug, later withdrawn for commercial (not safety) reasons | 1990s–2000s |
| FDA 503A action3 | US regulatory | Now handled as a compounded bulk substance, caught up in the FDA's ongoing peptide review | 2023 |
In plain terms: sermorelin genuinely worked as a growth-hormone-provoking agent in people — that's well established. What it was *approved for* was a narrow, mostly pediatric use, which is different from the general anti-aging framing it often gets today.
Class placement
Sermorelin, CJC-1295, and tesamorelin are all GHRH analogs — one half of the growth-hormone picture2. Ipamorelin and the GHRPs are the other half (GHS agonists). The three-way comparison sermorelin vs CJC-1295 vs ipamorelin maps it cleanly.
Latest research
- No large new efficacy trial has redefined sermorelin recently; its evidence base remains the well-established GHRH-stimulation and pediatric work1.
- The active development is regulatory: as a compounded peptide, sermorelin sits inside the FDA's ongoing 503A bulk-substances review, which is the thing most likely to change its status3.
- We update this section as new studies report.
The short version
Sermorelin is the original short GHRH analog — the 29-amino-acid fragment that carries full GHRH activity and prompts the body's own growth hormone. It has a real approved-drug history (Geref) as a diagnostic and pediatric treatment, but that product was withdrawn for commercial reasons and it now circulates as a compounded peptide. Its cousins CJC-1295 and tesamorelin share the mechanism; the difference is mostly duration. Educational overview only — see the class explainer.